Literature DB >> 17709410

In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity.

Herman F Staats1, S Munir Alam, Richard M Scearce, Shaun M Kirwan, Julia Xianzhi Zhang, William M Gwinn, Barton F Haynes.   

Abstract

Passive transfer of antibody may be useful for preexposure prophylaxis against biological agents used as weapons of terror, such as Bacillus anthracis. Studies were performed to evaluate the ability of anthrax antiprotective antigen (anti-PA) and antilethal factor (anti-LF) neutralizing monoclonal antibodies (mAbs) to protect against an anthrax lethal toxin (LeTx) challenge in a mouse model and to identify correlates of immunity to LeTx challenge. Despite having similar affinities for their respective antigens, anti-PA (3F11) and anti-LF (9A11), passive transfer of up to 1.5 mg of anti-PA 3F11 mAb did not provide significant protection when transferred to mice 24 h before LeTx challenge, while passive transfer of as low as 0.375 mg of anti-LF 9A11 did provide significant protection. Serum collected 24 h after passive transfer had LeTx-neutralizing activity when tested using a standard LeTx neutralization assay, but neutralization titers measured using this assay did not correlate with protection against LeTx challenge. However, measurement of LeTx-neutralizing serum responses with an LeTx neutralization assay in vitro employing the addition of LeTx to J774A.1 cells 15 min before the addition of the serum did result in neutralization titers that correlated with protection against LeTx challenge. Our results demonstrate that only the LeTx neutralization titers measured utilizing the addition of LeTx to J774A.1 cells 15 min before the addition of sample correlated with protection in vivo. Thus, this LeTx neutralization assay may be a more biologically relevant neutralization assay to predict the in vivo protective capacity of LeTx-neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709410      PMCID: PMC2168269          DOI: 10.1128/IAI.00529-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  59 in total

1.  Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans.

Authors:  P R Pittman; J A Mangiafico; C A Rossi; T L Cannon; P H Gibbs; G W Parker; A M Friedlander
Journal:  Vaccine       Date:  2000-09-15       Impact factor: 3.641

2.  Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B.

Authors:  W Xu; B A Smith-Franklin; P L Li; C Wood; J He; Q Du; G J Bhat; C Kankasa; H Katinger; L A Cavacini; M R Posner; D R Burton; T C Chou; R M Ruprecht
Journal:  J Hum Virol       Date:  2001 Mar-Apr

3.  Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.

Authors:  B M Price; A L Liner; S Park; S H Leppla; A Mateczun; D R Galloway
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

4.  Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin.

Authors:  P F Fellows; M K Linscott; B E Ivins; M L Pitt; C A Rossi; P H Gibbs; A M Friedlander
Journal:  Vaccine       Date:  2001-04-30       Impact factor: 3.641

5.  Death due to bioterrorism-related inhalational anthrax: report of 2 patients.

Authors:  L Borio; D Frank; V Mani; C Chiriboga; M Pollanen; M Ripple; S Ali; C DiAngelo; J Lee; J Arden; J Titus; D Fowler; T O'Toole; H Masur; J Bartlett; T Inglesby
Journal:  JAMA       Date:  2001-11-28       Impact factor: 56.272

6.  Clinical presentation of inhalational anthrax following bioterrorism exposure: report of 2 surviving patients.

Authors:  T A Mayer; S Bersoff-Matcha; C Murphy; J Earls; S Harper; D Pauze; M Nguyen; J Rosenthal; D Cerva; G Druckenbrod; D Hanfling; N Fatteh; A Napoli; A Nayyar; E L Berman
Journal:  JAMA       Date:  2001-11-28       Impact factor: 56.272

Review 7.  Anthrax toxin.

Authors:  R Bhatnagar; S Batra
Journal:  Crit Rev Microbiol       Date:  2001       Impact factor: 7.624

8.  Induction of systemic antifimbria and antitoxin antibody responses in Egyptian children and adults by an oral, killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine.

Authors:  E R Hall; T F Wierzba; C Ahrén; M R Rao; S Bassily; W Francis; F Y Girgis; M Safwat; Y J Lee; A M Svennerholm; J D Clemens; S J Savarino
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

9.  Passive transfer of protection against Bacillus anthracis infection in a murine model.

Authors:  R J Beedham; P C Turnbull; E D Williamson
Journal:  Vaccine       Date:  2001-08-14       Impact factor: 3.641

10.  In vitro correlate of immunity in a rabbit model of inhalational anthrax.

Authors:  M L Pitt; S F Little; B E Ivins; P Fellows; J Barth; J Hewetson; P Gibbs; M Dertzbaugh; A M Friedlander
Journal:  Vaccine       Date:  2001-09-14       Impact factor: 3.641

View more
  37 in total

Review 1.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

2.  Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Authors:  William M Gwinn; Shaun M Kirwan; Sheena H Wang; Kathleen A Ashcraft; Neil L Sparks; Catherine R Doil; Tom G Tlusty; Leslie S Casey; Susan K Hollingshead; David E Briles; Richard S Dondero; Anthony J Hickey; W Michael Foster; Herman F Staats
Journal:  Vaccine       Date:  2010-08-17       Impact factor: 3.641

3.  Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.

Authors:  Sherry R Crowe; Lori Garman; Renata J M Engler; A Darise Farris; Jimmy D Ballard; John B Harley; Judith A James
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

4.  Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women.

Authors:  Jiri Mestecky; Peter F Wright; Lucia Lopalco; Herman F Staats; Pamela A Kozlowski; Zina Moldoveanu; Rashada C Alexander; Rose Kulhavy; Claudia Pastori; Leonard Maboko; Gabriele Riedner; Yuwei Zhu; Terri Wrinn; Michael Hoelscher
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-22       Impact factor: 2.205

5.  A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.

Authors:  Conrad P Quinn; Carol L Sabourin; Nancy A Niemuth; Han Li; Vera A Semenova; Thomas L Rudge; Heather J Mayfield; Jarad Schiffer; Robert S Mittler; Chris C Ibegbu; Jens Wrammert; Rafi Ahmed; April M Brys; Robert E Hunt; Denyse Levesque; James E Estep; Roy E Barnewall; David M Robinson; Brian D Plikaytis; Nina Marano
Journal:  Clin Vaccine Immunol       Date:  2012-08-29

6.  Neutralizing monoclonal antibody to edema toxin and its effect on murine anthrax.

Authors:  Lisa Winterroth; Johanna Rivera; Antonio S Nakouzi; Ekaterina Dadachova; Arturo Casadevall
Journal:  Infect Immun       Date:  2010-04-12       Impact factor: 3.441

7.  Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.

Authors:  Melissa L Nguyen; Sherry R Crowe; Sridevi Kurella; Simon Teryzan; Brian Cao; Jimmy D Ballard; Judith A James; A Darise Farris
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

8.  Bacillus anthracis lethal toxin represses MMTV promoter activity through transcription factors.

Authors:  Zhigang Kang; Jeanette I Webster Marketon; Antoinette Johnson; Esther M Sternberg
Journal:  J Mol Biol       Date:  2009-04-21       Impact factor: 5.469

9.  Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen.

Authors:  Cassandra D Kelly-Cirino; Nicholas J Mantis
Journal:  Infect Immun       Date:  2009-08-24       Impact factor: 3.441

10.  Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infection.

Authors:  Ronit Rosenfeld; Hadar Marcus; Einat Ben-Arie; Bat-El Lachmi; Adva Mechaly; Shaul Reuveny; Orit Gat; Ohad Mazor; Arie Ordentlich
Journal:  PLoS One       Date:  2009-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.